Abstract
Cannabidiol (CBD), a nonpsychoactive cannabinoid, was found to be converted to 9α-hydroxyhexahydrocannabinol (9α-OH-HHC) and 8-hydroxy-iso-hexahydrocannabinol (8-OH-iso-HHC) together with Δ9-tetrahydrocannabinol (Δ9-THC), a psychoactive cannabinoid, and cannabinol in artificial gastric juice. These cannabinoids were identified by gas chromatography-mass spectrometry (GC-MS) by comparison with the spectral data of the authentic compounds. Pharmacological effects of 9α-OH-HHC and 8-OH-iso-HHC in mice were examined using catalepsy, hypothermia, pentobarbital-induced sleep prolongation, and antinociception against acetic acid-induced writhing as indices. The ED50 values (effective dose producing a 50% reduction of control; mg/kg, i.v.) of 9α-OH-HHC and 8-OH-iso-HHC for the cataleptogenic effect were 8.0 and 30.4, respectively. 8-OH-iso-HHC (10 mg/kg, i.v.) produced a significant hypothermia from 15 to 90 min after administration, although 9α-OH-HHC failed to induce such an effect at the same dose. However, both HHCs (10 mg/kg, i.v.) significantly prolonged pentobarbital-induced sleeping time by 1.8 to 8.0 times as compared with the control solution with 1% Tween 80-saline. The ED50 values (mg/kg, i.v.) of 9α-OH-HHC and 8-OH-iso-HHC for the antinociceptive effect were 14.1 and 39.4, respectively. The present study demonstrated that CBD can be converted to Δ9-THC and its related cannabinoids, 9α-OH-HHC and 8-OH-iso-HHC, in artificial gastric juice, and that these HHCs show Δ9-THC-like effects in mice, although their pharmacological effects were less potent than those of Δ9-THC.
References
Mechoulam R, Shani A, Edery H, Grunfeld Y (1970) The chemical basis of hashish activity. Science 169:383–393
Hollister LE (1973) Cannabidiol and cannabinol in man. Experientia 29:825–826
Hollister LE (1974) Structure-activity relationships in man of cannabis constituents and homologs and metabolites for Δ9-tetrahydrocannabinol. Pharmacology 11:3–11
Adams R, Pease DC, Cain CK, Clark JH (1940) Structure of cannabidiol. VI. Isomerization of cannabidiol to tetrahydrocannabinol, a physiologically active product. Conversion of cannabidiol to cannabinol. J Am Chem Soc 62:2402–2405
Adams R, Cain CK, McPhee WD, Wearn RB (1941) Structure of cannabidiol. XII. Isomerization to tetrahydrocannabinols. J Am Chem Soc 63:2209–2213
Gaoni Y, Mechoulam R (1966) Hashish-VII, the isomerization of cannabidiol to tetrahydrocannabinols. Tetrahedron 22:1481–1488
Gaoni Y, Mechoulam R (1968) The iso-tetrahydrocannabinols. Israel J Chem 6:679–690
Quarles W, Ellman G, Jones R (1973) Toxicology of marihuana: conditions for conversion of cannabidiol to THC upon smoking. Clin Toxicol 6:211–216
Nagai K, Watanabe K, Narimatsu S, Gohda H, Matsunaga T, Yamamoto I, Yoshimura H (1993) In vitro metabolic formation of a new metabolite, 6β-hydroxymethyl-Δ9-tetrahydrocannabinol from cannabidiol through an epoxide intermediate and its pharmacological effects on mice. Biol Pharm Bull 16:1008–1013
Aramaki H, Tomiyasu N, Yoshimura H, Tsukamoto H (1968) Forensic chemical study on marihuana. I. A detection method of the principal constituents by thin-layer and gas chromatographies. Chem Pharm Bull 16:822–826
Petrzilka T, Demuth M (1974) Synthese von (−)-11-hydroxy-Δ8-6a,10a-trans-tetrahydrocannabinol. Helv Chim Acta 57:121–150
Yoshimura H, Watanabe K, Oguri K, Fujiwara M, Ueki S (1978) Synthesis and pharmacological activity of a phosphate ester of Δ8-tetrahydrocannabinol. J Med Chem 21:1079–1081
Watanabe K, Kijima T, Narimatsu S, Nishikami J, Yamamoto I, Yoshimura H (1990) Comparison of pharmacological effects of tetrahydrocannabinols and their 11-hydroxymetabolites in mice. Chem Pharm Bull 38:2317–2319
Litchfield JT, Wilcoxon F (1949) A simplified method of evaluating dose-effect experiments. J Pharmacol Exp Ther 96:99–113
Wilson RS, May EL, Martin BR, Dewey WL (1976) 9-Nor-9-hydroxyhexahydrocannabinols. Synthesis, some behavioral and analgesic properties, and comparison with the tetrahydrocannabinols. J Med Chem 19:1165–1167
Skinner WA, Rackur G, Uyeno E (1979) Structure-activity studies on tetrahydro-and hexahydrocannabinol derivatives. J Pharm Sci 68:330–332
Ganz AJ, Waser PG (1980) Prufung der pharmakologischen wirkung einiger synthetischer Cannabinoide an der Maus. Arzneim-Forsch 30:471–477
Narimatsu S, Yamamoto I, Watanabe K, Yoshimura H (1983) 9α, 10α-Epoxyhexahydrocannabinol formation from Δ9-tetrahydrocannabinol by liver microsomes of phenobarbital-treated mice and its pharmacological activities in mice. J Pharmacobio-Dyn 6:558–564
Holtzman D, Lovell RA, Jaffe JH, Freedman DX (1969) l-Δ9-Tetrahydrocannabinol: neurochemical and behavioral effects in the mouse. Science 163:1464–1467
Lomax P (1971) Acute tolerance to the hypothermic effect of marihuana in the rat. Res Commun Chem Path Pharmacol 2:159–167
Haavik CO, Hardman HF (1973) Evaluation of the hypothermic action of tetrahydrocannabinols in mice and squirrel monkeys. J Pharmacol Exp Ther 187:568–574
Zimmer A, Zimmer AM, Hohmann AG, Herkenham M, Bonner TI (1999) Increased mortality, hypoactivity, and hypoalgesia in cannabinoid CB1 receptor knockout mice. Proc Natl Acad Sci USA 96:5780–5785
Fernandes M, Schabarek A, Coper H, Hill R (1974) Modification of Δ9-THC actions by cannabinol and cannabidiol in the rat. Psychopharmacology 38:329–338
Turkanis SA, Cely W, Olsen DM, Karler R (1974) Anticonvulsant properties of cannabidiol. Res Commun Chem Path Pharmacol 8:231–246
Chiu P, Karler R, Craven C, Olsen DM, Turkanis SA (1975) The influence of Δ9-tetrahydrocannabinol, cannabinol and cannabidiol on tissue oxygen consumption. Res Commun Chem Path Pharmacol 12:267–286
Bloom AS, Johnson KM, Dewey WL (1978) The effects of cannabinoids on body temperature and brain catecholamine synthesis. Res Commun Chem Path Pharmacol 20:51–57
Yamamoto I, Watanabe K, Kuzuoka K, Narimatsu S, Yoshimura H (1987) The pharmacological activity of cannabinol and its major metabolite, 11-hydroxycannabinol. Chem Pharm Bull 35:2144–2147
Paton WD, Pertwee RG (1972) Effects of cannabis and certain of its constituents on pentobarbitone sleeping time and phenazone metabolism. Br J Pharmacol 44:250–261
Coldwell BB, Bailey K, Paul CJ, Anderson G (1974) Interaction of cannabinoids with pentobarbital in rats. Toxicol Appl Pharmacol 29:59–69
Siemens AJ, Kalant H, Khana M, Marshman J, Ho G (1974) Effect of cannabis on pentobarbital-induced sleeping time and pentobarbital metabolism in the rat. Biochem Pharmacol 23:477–488
Borys HK, Ingall GB, Karler R (1979) Development of tolerance to the prolongation of hexobarbitone sleeping time caused by cannabidiol. Br J Pharmacol 67:93–101
Watanabe K, Arai M, Narimatsu S, Yamamoto I, Yoshimura H (1987) Self-catalyzed inactivation of cytochrome P-450 during microsomal metabolism of cannabidiol. Biochem Pharmacol 36:3371–3377
Buxbaum DM (1972) Analgesic activity of Δ9-tetrahydrocannabinol in the rat and mouse. Psychopharmacologia 25:275–280
Sofia RD, Nalepa SD, Harakal JJ, Vassar HB (1973) Antiedema and analgesic properties of Δ9-tetrahydrocannabinol (THC). J Pharmacol Exp Ther 186:646–655
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Watanabe, K., Itokawa, Y., Yamaori, S. et al. Conversion of cannabidiol to Δ9-tetrahydrocannabinol and related cannabinoids in artificial gastric juice, and their pharmacological effects in mice. Forensic Toxicol 25, 16–21 (2007). https://doi.org/10.1007/s11419-007-0021-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11419-007-0021-y